I wouldn't mind a right issue for existing holders, but I'm inclined to think it is bigger than that. They are going to need some serious working capital to ramp up production for ARDS treatment. Given the mortality rate in the US I see the current trial being stopped due to efficacy and Remestecel being the new standard of care. when that happens MSB will burn through $60m very quickly ramping up production and distribution- they are going to need cash from someone. My only question is who is the 'someone'? Tasly, JCR, Gruenthal, you and me, instos?
Ann: Trading Halt, page-74
-
- There are more pages in this discussion • 860 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.085(7.69%) |
Mkt cap ! $1.358B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.20 | $1.09 | $13.21M | 11.37M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 75212 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |